Details:
Results from the trial presented no significant safety concerns. The neutralizing antibody titers 14 days after the second vaccination of DS-5670 have demonstrated acquirement of adequate immunity.
Lead Product(s): mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DS-5670
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Under the terms of the parties’ new agreement, the clinical development and commercialization of ASP3772, as well as royalties tied to the commercialization of Affinivax’s next generation pneumococcal vaccine products designed to treat Streptococcus pneuomoniae.
Lead Product(s): 24-valent Streptococcus Pneumoniae Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: ASP3772
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Affinivax
Deal Size: Undisclosed Upfront Cash: $65.0 million
Deal Type: Agreement February 28, 2022
Details:
DS-5670, an mRNA vaccine against COVID-19 using a novel nucleic acid delivery technology in phase 1/2/3 study evaluate safety and efficacy in healthy Japanese adults who completed initial vaccination also induced neutralizing activities against Omicron variant in animal model.
Lead Product(s): mRNA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DS-5670
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2022
Details:
The grant will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson’s bedaquiline, for patients with drug-susceptible pulmonary tuberculosis (DS-TB).
Lead Product(s): OPC-167832,Delamanid,Bedaquiline
Therapeutic Area: Infections and Infectious Diseases Product Name: OPC-167832
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $17.8 million Upfront Cash: Undisclosed
Deal Type: Funding August 10, 2021
Details:
The phase 1/2 trial is being conducted in Japan in a total of 152 healthy adults, including elderly individuals, to evaluate the safety and immunogenicity of the vaccine and thereby estimate the recommended dose of DS-5670.
Lead Product(s): DS-5670
Therapeutic Area: Infections and Infectious Diseases Product Name: DS-5670
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
First subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine candidate in Japan.
Lead Product(s): TAK-019
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
First participant has been dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd. TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine candidate.
Lead Product(s): TAK-919
Therapeutic Area: Infections and Infectious Diseases Product Name: mRNA-1273
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Moderna Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021